Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients

Smith, Ruben LU ; Cullen, Nicholas C. LU ; Pichet Binette, Alexa LU ; Leuzy, Antoine LU ; Blennow, Kaj LU ; Zetterberg, Henrik LU ; Klein, Gregory ; Borroni, Edilio ; Ossenkoppele, Rik LU and Janelidze, Shorena LU , et al. (2023) In Alzheimer's and Dementia 19(6). p.2497-2507
Abstract

Introduction: Biomarkers for the prediction of cognitive decline in patients with amnestic mild cognitive impairment (MCI) and amnestic mild dementia are needed for both clinical practice and clinical trials. Methods: We evaluated the ability of tau-PET (positron emission tomography), cortical atrophy on magnetic resonance imaging (MRI), baseline cognition, apolipoprotein E gene (APOE) status, plasma and cerebrospinal fluid (CSF) levels of phosphorylated tau-217, neurofilament light (NfL), and amyloid beta (Aβ)42/40 ratio (individually and in combination) to predict cognitive decline over 2 years in BioFINDER-2 and Alzheimer's Disease Neuroimaging Initiative (ADNI). Results: Baseline tau-PET and a composite baseline cognitive... (More)

Introduction: Biomarkers for the prediction of cognitive decline in patients with amnestic mild cognitive impairment (MCI) and amnestic mild dementia are needed for both clinical practice and clinical trials. Methods: We evaluated the ability of tau-PET (positron emission tomography), cortical atrophy on magnetic resonance imaging (MRI), baseline cognition, apolipoprotein E gene (APOE) status, plasma and cerebrospinal fluid (CSF) levels of phosphorylated tau-217, neurofilament light (NfL), and amyloid beta (Aβ)42/40 ratio (individually and in combination) to predict cognitive decline over 2 years in BioFINDER-2 and Alzheimer's Disease Neuroimaging Initiative (ADNI). Results: Baseline tau-PET and a composite baseline cognitive score were the strongest independent predictors of cognitive decline. Cortical thickness and NfL provided some additional information. Using a predictive algorithm to enrich patient selection in a theoretical clinical trial led to a significantly lower required sample size. Discussion: Models including baseline tau-PET and cognition consistently provided the best prediction of change in cognitive function over 2 years in patients with amnestic MCI or mild dementia.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
AD, blood biomarkers, cognition, PET, tau
in
Alzheimer's and Dementia
volume
19
issue
6
pages
2497 - 2507
publisher
Wiley
external identifiers
  • scopus:85144164556
  • pmid:36516028
ISSN
1552-5260
DOI
10.1002/alz.12875
language
English
LU publication?
yes
id
34a082f2-ec1c-44df-80b0-6d1e1f9e4a0b
date added to LUP
2023-01-24 13:32:00
date last changed
2024-06-13 09:39:18
@article{34a082f2-ec1c-44df-80b0-6d1e1f9e4a0b,
  abstract     = {{<p>Introduction: Biomarkers for the prediction of cognitive decline in patients with amnestic mild cognitive impairment (MCI) and amnestic mild dementia are needed for both clinical practice and clinical trials. Methods: We evaluated the ability of tau-PET (positron emission tomography), cortical atrophy on magnetic resonance imaging (MRI), baseline cognition, apolipoprotein E gene (APOE) status, plasma and cerebrospinal fluid (CSF) levels of phosphorylated tau-217, neurofilament light (NfL), and amyloid beta (Aβ)<sub>42/40</sub> ratio (individually and in combination) to predict cognitive decline over 2 years in BioFINDER-2 and Alzheimer's Disease Neuroimaging Initiative (ADNI). Results: Baseline tau-PET and a composite baseline cognitive score were the strongest independent predictors of cognitive decline. Cortical thickness and NfL provided some additional information. Using a predictive algorithm to enrich patient selection in a theoretical clinical trial led to a significantly lower required sample size. Discussion: Models including baseline tau-PET and cognition consistently provided the best prediction of change in cognitive function over 2 years in patients with amnestic MCI or mild dementia.</p>}},
  author       = {{Smith, Ruben and Cullen, Nicholas C. and Pichet Binette, Alexa and Leuzy, Antoine and Blennow, Kaj and Zetterberg, Henrik and Klein, Gregory and Borroni, Edilio and Ossenkoppele, Rik and Janelidze, Shorena and Palmqvist, Sebastian and Mattsson-Carlgren, Niklas and Stomrud, Erik and Hansson, Oskar}},
  issn         = {{1552-5260}},
  keywords     = {{AD; blood biomarkers; cognition; PET; tau}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{2497--2507}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients}},
  url          = {{http://dx.doi.org/10.1002/alz.12875}},
  doi          = {{10.1002/alz.12875}},
  volume       = {{19}},
  year         = {{2023}},
}